In November 2021, the FDA approved semaglutide specifically for chronic weight management at higher doses under the brand name Wegovy, formally recognizing weight loss as a primary therapeutic indication
Contact our team to learn more about available weight loss treatments
For those exploring medical weight loss options, understanding the differences between these medications can help facilitate informed conversations with a qualified healthcare provider about the most appropriate path forward
How to interpret the labs Reduced intake can change diabetes medication needs and dehydration risk
For comparative context, researchers may reference Semaglutide, a selective GLP-1 receptor agonist, and Tirzepatide, a dual GIP/GLP-1 receptor agonist, when examining how incremental receptor targeting across this compound class affects metabolic pathway outcomes
IVY RXs FAQ says it uses pharmacies compliant with 503B/USP standards. These are different things